03Dec 2021
Reduced Dose BCG in an Era of BCG Shortage: Real‐World Experience from a Tertiary Cancer Centre

Reduced Dose BCG in an Era of BCG Shortage: Real‐World Experience from a Tertiary Cancer Centre

The global bacillus Calmette‐Guérin (BCG) shortage has prompted the use of alternative treatment strategies for patients with intermediate‐ and high‐risk non‐muscle invasive bladder cancer (NMIBC). One such strategy is split‐vial dosing which allows several patients to be treated from a single vial of BCG. We evaluated the impact of one‐third dose BCG on oncological outcomes in a large cohort of patients with NMIBC treated with adequate BCG in a real‐world setting. We performed an institutional review board‐approved review of patients with NMIBC treated with adequate BCG at our institution between 2000 and 2020. Patients were stratified according to whether they had received one‐third dose (1/3D) BCG or full dose (FD) BCG. Time to recurrence, time to progression and cancer‐specific survival were estimated using Kaplan‐Meier methods...

  • #urology

Like

Save

Share